0001193125-17-309956.txt : 20171013 0001193125-17-309956.hdr.sgml : 20171013 20171013170405 ACCESSION NUMBER: 0001193125-17-309956 CONFORMED SUBMISSION TYPE: 15-12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20171013 DATE AS OF CHANGE: 20171013 EFFECTIVENESS DATE: 20171013 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kite Pharma, Inc. CENTRAL INDEX KEY: 0001510580 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-36508 FILM NUMBER: 171137049 BUSINESS ADDRESS: STREET 1: 2225 COLORADO AVENUE CITY: SANTA MONICA STATE: CA ZIP: 90404 BUSINESS PHONE: (310) 824-9999 MAIL ADDRESS: STREET 1: 2225 COLORADO AVENUE CITY: SANTA MONICA STATE: CA ZIP: 90404 15-12B 1 d462237d1512b.htm 15-12B 15-12B

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-36508

 

 

Kite Pharma, Inc.

(Exact name of registrant as specified in its charter)

 

 

2555 Colorado Avenue,

Santa Monica, CA 90404,

(310) 824-9999    

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, par value $0.01 per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)   ☒
Rule 12g-4(a)(2)   ☐
Rule 12h-3(b)(1)(i)   ☒
Rule 12h-3(b)(1)(ii)   ☐
Rule 15d-6   ☐
Rule 15d-22(b)   ☐

Approximate number of holders of record as of the certification or notice date:                 1                

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Kite Pharma, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date:   October 13, 2017     By:   /s/ Robin L. Washington
        Name:  Robin L. Washington
        Title:    President and Treasurer